title: Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
authors.affiliation: University of Milano Bicocca, Dept. of Hematology, Clinical Research Unit, S. Gerardo Hospital, Monza, Italy. carlo.gambacorti@unimib.it
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: Rocco
authors.initials: R
authors.lastname: Piazza
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D001786:Blood Glucose / Q000378:metabolism; D015331:Cohort Studies; D003251:Constriction, Pathologic / Q000097:blood / Q000139:chemically induced / Q000601:surgery; D003324:Coronary Artery Disease / Q000139:chemically induced / Q000628:therapy; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005215:Fasting / Q000097:blood; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood / Q000139:chemically induced* / Q000601:surgery; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D001549:Benzamides; D001786:Blood Glucose; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib